Magnetic Resonance Spectroscopy Imaging (MRSI) and brain functional Magnetic Resonance Imaging (fMRI) for radiotherapy treatment planning of glioma

Technology in Cancer Research and Treatment

Volumn 7, Issue 5, 2008, Pages 349-362

  Chang, Jenghwa ^a   Thakur, Sunitha B ^b   Huang, Wei ^b   Narayana, Ashwatha ^a  

^a NEW YORK UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

fMRI; Glioma; MRSI; Radiotherapy treatment planning

Indexed keywords

BRAIN REGION; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; FEASIBILITY STUDY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLIOMA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION DOSE DISTRIBUTION; REVIEW; SIMULATION; STEREOTACTIC RADIOSURGERY; TREATMENT PLANNING;

EID: 53549107774     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Ling, C. C., Humm, J., Larson, S., et al. Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. International Journal of Radiation Oncology Biology Physics 47, 551-560 (2000).
2. Narayana, A., Chang, J., Thakur, S., et al. Use of MR spectroscopy and functional imaging in the treatment planning of gliomas. British Journal of Radiology 80, 347-354 (2007).
3. Dean, B. L., Drayer, B. P., Bird, C. R., et al. Gliomas: Classification with MR imaging. Radiology 174, 411-415 (1990).
4. Law, M., Yang, S., Wang, H., et al. Glioma Grading: Sensitivity, Specificity, and Predictive Values of Perfusion MR Imaging and Proton MR Spectroscopic Imaging Compared with Conventional MR Imaging. American Journal of Neuroradiology 24, 1989-1998 (2003).
5. Nelson, S. J., Vigneron, D. B., Dillon, W. P. Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI. NMR Biomed 12, 123-138 (1999).
6. Nelson, S. J., Graves, E., Pirzkall, A., et al. In vivo molecular imaging for planning radiation therapy of gliomas: An application of 1H MRSI. Journal of Magnetic Resonance Imaging 16, 464-476 (2002).
7. Pirzkall, A., Li, X., Oh, J., et al. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys 59, 126-137 (2004).
8. Fan, G., Sun, B., Wu, Z., et al. In vivo single-voxel proton MR spectroscopy in the differentiation of high-grade gliomas and solitary metastases. Clinical Radiology 59, 77-85 (2004).
9. Grand, S., Tropres, I., Hoffmann, D., et al. Proton magnetic resonance spectroscopy (1H-MRS) for the diagnosis of brain tumors and the evaluation of treatment. Neurochirurgie 51, 299-308 (2005).
10. Hollingworth, W., Medina, L. S., Lenkinski, R. E., et al. A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. American Journal of Neuroradiology 27, 1404-1411 (2006).
11. Laprie, A., Catalaa, I., Cassol, E., et al. Proton Magnetic Resonance Spectroscopic Imaging in Newly Diagnosed Glioblastoma: Predictive Value for the Site of Postradiotherapy Relapse in a Prospective Longitudinal Study. International Journal of Radiation Oncology Biology Physics 70, 773-781 (2008).
12. Park, I., Tamai, G., Lee, M. C., et al. Patterns of Recurrence Analysis in Newly Diagnosed Glioblastoma Multiforme After Three-Dimensional Conformai Radiation Therapy With Respect to Pre-Radiation Therapy Magnetic Resonance Spectroscopic Findings. International Journal of Radiation Oncology Biology Physics 69, 381-389 (2007).
13. Dhermain, F., Ducreux, D., Bidault, F., et al. Impact of new functional imaging modalities on radiation therapy regimen for glioblastoma. Apport des nouvelles techniques d'imagerie a? la planification radiothe? rapique des patients porteurs de glioblastome polymorphe 92, 333-342 (2005).
14. Miften, M. M., Das, S. K., Su, M., et al. Incorporation of functional imaging data in the evaluation of dose distributions using the generalized concept of equivalent uniform dose. Physics in Medicine and Biology 49, 1711-1721 (2004).
15. Graves, E. E., Pirzkall, A., Nelson, S. J., et al. Registration of magnetic resonance spectroscopic imaging to computed tomography for radiotherapy treatment planning. Medical Physics 28, 2489-2496 (2001).
16. Chang, J., Thakur, S., Perera, G., et al. Image-fusion of MR spectroscopic images for treatment planning of gliomas. Medical Physics 33, 32-40 (2006).
17. Chang, J., Kowalski, A., Hou, B., et al. Feasibility Study of Intensity-Modulated Radiotherapy (IMRT) Treatment Planning Using Brain Functional MRI. Medical Dosimetry 33, 42-47 (2008).
18. Narayana, A., Leibel, S. A. Adult brain tumors. In Textbook of Radiation Oncology, 2nd Ed, pp. 463-495. Eds., Leibel, S. A., Phillips, T. L. Philadelphia: Saunders (2002).
19. Leibel, S. A., Scott, C. B., Loeffler, J. S. Contemporary approaches to the treatment of malignant gliomas with radiation therapy. Seminars in Oncology 21, 198-219 (1994).
20. Prados, M. D. Treatment strategies for patients with recurrent brain tumors. Seminars in Radiation Oncology 1, 62-68 (1991).
21. Kleihues, P., Burger, P. C., Scheithauer, B. W. The new WHO classification of brain tumours. Brain Pathology 3, 255-268 (1993).
22. Simpson, J. R., Horton, J., Scott, C., et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26, 239-244 (1993).
23. Randomized Trial of Procarbazine, Lomustine, and Vincristine in the Adjuvant Treatment of High-Grade Astrocytoma: A Medical Research Council Trial. Journal of Clinical Oncology 19, 509-518 (2001).
24. Mirimanoff, R.-O., Gorlia, T., Mason, W., et al. Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized Trial. Journal of Clinical Oncology 24, 2563-2569 (2006).
25. Stupp, R., Mason, W. P., van den Bent, M. J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987-996 (2005).
26. Curran, W. J., Jr., Scott, C. B., Horton, J., et al. Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol 12, 219-227 (1992).
27. Prados, M. D., Gutin, P. H., Phillips, T. L., et al. Highly anaplastic astrocytoma: a review of 357 patients treated between 1977 and 1989. Int J Radiat Oncol Biol Phys 23, 3-8 (1992).
28. Narayana, A., Yamada, J., Berry, S., et al. Intensity-modulated radiotherapy in high-grade gliomas: Clinical and dosimetric results. International Journal of Radiation Oncology Biology Physics 64, 892-897 (2006).
29. Bleehen, N. M., Stenning, S. P. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. British Journal of Cancer 64, 769-774 (1991).
30. Lee, S. W., Fraass, B. A., Marsh, L. H., et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: A quantitative dosimetric study. International Journal of Radiation Oncology Biology Physics 43, 79-88 (1999).
31. Roman, D. D., Sperduto, P. W. Neuropsychological effects of cranial radiation: Current knowledge and future directions. International Journal of Radiation Oncology Biology Physics 31, 983-998 (1995).
32. Butler, J., Rapp, S., Shaw, E. Managing the cognitive effects of brain tumor radiation therapy. Current Treatment Options in Oncology 7, 517-523 (2006).
33. Halperin, E. C., Bentel, G., Heinz, E. R., et al. Radiation therapy treatment planning in supratentorial glioblastoma multiforme: an analysis based on post mortem topographic anatomy with CT correlations. Int J Radiat Oncol Biol Phys 17, 1347-1350 (1989).
34. Burger, P. C., Heinz, E. R., Shibata, T., et al. Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 68, 698-704 (1988).
35. Chang, E. L., Akyurek, S., Avalos, T., et al. Evaluation of Peritumoral Edema in the Delineation of Radiotherapy Clinical Target Volumes for Glioblastoma. International Journal of Radiation Oncology Biology Physics 68, 144-150 (2007).
36. Just, M., Thelen, M. Tissue characterization with T1, T2, and proton density values: Results in 160 patients with brain tumors. Radiology 169, 779-785 (1988).
37. Earnest, Iv. F., Kelly, P. J., Scheithauer, B. W., et al. Cerebral astrocytomas: Histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 166, 823-827 (1988).
38. Tsuchida, T., Takeuchi, H., Okazawa, H., et al. Grading of brain glioma with 1-11C-acetate PET: comparison with 18F-FDG PET. Nuclear Medicine and Biology 35, 171-176 (2008).
39. Mahasittiwat, P., Mizoe, J.-e., Hasegawa, A., et al. 1-[METHYL-11C] Methionine Positron Emission Tomography for Target Delineation in Malignant Gliomas: Impact on Results of Carbon Ion Radiotherapy. International Journal of Radiation Oncology Biology Physics 70, 515-522 (2008).
40. Law, M., Yang, S., Babb, J. S., et al. Comparison of Cerebral Blood Volume and Vascular Permeability from Dynamic Susceptibility Contrast-Enhanced Perfusion MR Imaging with Glioma Grade. American Journal of Neuroradiology 25, 746-755 (2004).
41. Provenzale, J. M., York, G., Moya, M. G., et al. Correlation of Relative Permeability and Relative Cerebral Blood Volume in High-Grade Cerebral Neoplasms. American Journal of Roentgenology 187, 1036-1042 (2006).
42. Hamstra, D. A., Galban, C. J., Meyer, C. R., et al. Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall Survival. Journal of Clinical Oncology JCO.2007.2015.2363 (2008).
43. Oshiro, S., Tsugu, H., Komatsu, F., et al. Quantitative assessment of gliomas by proton magnetic resonance spectroscopy. Anticancer Res 27, 3757-3763 (2007).
44. Laack, N. N., Brown, P. D. Cognitive sequelae of brain radiation in adults. Semin Oncol 31, 702-713 (2004).
45. Taphoorn, M. Neurocognitive sequelae in the treatment of low-grade gliomas. Seminars in Oncology 30, 45-48 (2003).
46. Bottomley, P. A. Spatial localization in NMR spectroscopy in vivo. Annals of the New York Academy of Sciences 508, 333-348 (1987).
47. Haase, A., Frahm, J., Matthaei, D. MR imaging using stimulated echoes (STEAM). Radiology 160, 787-790 (1986).
48. Kaminogo, M., Ishimaru, H., Morikawa, M., et al. Diagnostic potential of short echo time MR spectroscopy of gliomas with singlevoxel and point-resolved spatially localised proton spectroscopy of brain. Neuroradiology 43, 353-363 (2001).
49. Shimizu, H., Kumabe, T., Tominaga, T., et al. Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. American Journal of Neuroradiology 17, 737-747 (1996).
50. Lichy, M. P., Bachert, P., Hamprecht, F., et al. Application of 1H MR spectroscopic imaging in radiation oncology: Choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors. RoFo Fortschritte auf dem Gebiete der Rontgenstrahlen und der Neuen Bildgebenden Verfahren 178, 627-633 (2006).
51. Brown, T. R., Kincaid, B. M., Ugurbil, K. NMR chemical shift imaging in three dimensions. Proceedings of the National Academy of Sciences of the United States of America 79, 3523-3526 (1982).
52. Ogawa, S., T., M. L., A, R. K., et al. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proceedings of the National Academy of Sciences of the United States of America 87, 9868-9872 (1990).
53. Norris, D. G. Principles of magnetic resonance assessment of brain function. J Magn Reson Imaging 23, 794-807 (2006).
54. Cox, R. W. AFNI: Software for analysis and visualization of functional magnetic resonance neuroimages. Computers and Biomedical Research 29, 162-173 (1996).
55. Cox, R. W., Hyde, J. S. Software tools for analysis and visualization of fMRI data. NMR in Biomedicine 10, 171-178 (1997).
56. Rand, S. D., Prost, R., Li, S. J. Proton MR spectroscopy of the brain. Neuroimaging Clin N Am 9, 379-395 (1999).
57. Nelson, S. J. Multivoxel Magnetic Resonance Spectroscopy of Brain Tumors. Molecular Cancer Therapeutics 2, 497-507 (2003).
58. McKnight, T. R., Von dem Bussche, M. H., Vigneron, D. B., et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. Journal of Neurosurgery 97, 794-802 (2002).
59. Fountas, K. N., Kapsalaki, E. Z., Vogel, R. L., et al. Noninvasive histologic grading of solid astrocytomas using proton magnetic resonance spectroscopy. Stereotactic and Functional Neurosurgery 82, 90-97 (2004).
60. McKnight, T. R., Lamborn, K. R., Love, T. D., et al. Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. Journal of Neurosurgery 106, 660-666 (2007).
61. Pirzkall, A., Nelson, S. J., McKnight, T. R., et al. Metabolic imaging of low-grade gliomas with three-dimensional magnetic resonance spectroscopy. International Journal of Radiation Oncology Biology Physics 53, 1254-1264 (2002).
62. Howe, F. A., Barton, S. J., Cudlip, S. A., et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magnetic Resonance in Medicine 49, 223-232 (2003).
63. Li, X., Lu, Y., Pirzkall, A., et al. Analysis of the spatial characteristics of metabolic abnormalities in newly diagnosed glioma patients. Vol 16, 229-237 (2002).
64. Zaider, M., Zelefsky, M. J., Lee, E. K., et al. Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. International Journal of Radiation Oncology Biology Physics 47, 1085-1096 (2000).
65. DiBiase, S. J., Hosseinzadeh, K., Gullapalli, R. P., et al. Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics 52, 429-438 (2002).
66. Ando, K., Ishikura, R., Nagami, Y., et al. [Usefulness of Cho/Cr ratio in proton MR spectroscopy for differentiating residual/recurrent glioma from non-neoplastic lesions]. Nippon Igaku Hoshasen Gakkai Zasshi 64, 121-126 (2004).
67. McKnight, T. R., Noworolski, S. M., Vigneron, D. B., et al. An automated technique for the quantitative assessment of 3D-MRSI data from patients with glioma. Journal of Magnetic Resonance Imaging 13, 167-177 (2001).
68. Pirzkall, A., McKnight, T. R., Graves, E. E., et al. MR-spectroscopy guided target delineation for high-grade gliomas. International Journal of Radiation Oncology Biology Physics 50, 915-928 (2001).
69. Li, B. S. Y., Babb, J. S., Soher, B. J., et al. Reproducibility of 3D proton spectroscopy in the human brain. Magnetic Resonance in Medicine 47, 439-446 (2002).
70. Simmons, A., Smail, M., Moore, E., et al. Serial precision of metabolite peak area ratios and water referenced metabolite peak areas in proton MR spectroscopy of the human brain. Magnetic Resonance Imaging 16, 319-330 (1998).
71. Liu, W. C., Schulder, M., Narra, V., et al. Functional magnetic resonance imaging aided radiation treatment planning. Medical Physics 27, 1563-1572 (2000).
72. Turner, R. How much codex can a vein drain? Downstream dilution of activation-related cerebral blood oxygenation changes. NeuroImage 16, 1062-1067 (2002).
73. Garcia-Alvarez, R., Liney, G. P., Beavis, A. W. Repeatability of functional MRI for conformai avoidance radiotherapy planning. Journal of Magnetic Resonance Imaging 23, 108-114 (2006).
74. Kim, M. J., Holodny, A. I., Hou, B. L., et al. The effect of prior surgery on blood oxygen level-dependent functional MR imaging in the preoperative assessment of brain tumors. AJNR Am J Neuroradiol 26, 1980-1985 (2005).
75. Hou, B. L., Bradbury, M., Peck, K. K., et al. Effect of brain tumor neovasculature defined by rCBV on BOLD fMRI activation volume in the primary motor cortex. NeuroImage 32, 489-497 (2006).
76. Liu, W. C., Feldman, S. C., Schulder, M., et al. The effect of tumour type and distance on activation in the motor cortex. Neuroradiology 47, 813-819 (2005).
77. Fujiwara, N., Sakatani, K., Katayama, Y., et al. Evoked-cerebral blood oxygenation changes in false-negative activations in BOLD contrast functional MRI of patients with brain tumors. NeuroImage 21, 1464-1471 (2004).
78. Ludemann, L., Forschler, A., Grieger, W., et al. BOLD signal in the motor cortex shows a correlation with the blood volume of brain tumors. J Magn Reson Imaging 23, 435-443 (2006).
79. Krings, T., Topper, R., Willmes, K., et al. Activation in primary and secondary motor areas in patients with CNS neoplasms and weakness. Neurology 58, 381-390 (2002).
80. Carpentier, A. C., Constable, R. T., Schlosser, M. J., et al. Patterns of functional magnetic resonance imaging activation in association with structural lesions in the rolandic region: a classification system. J Neurosurg 94, 946-954 (2001).
81. Beyer, T., Townsend, D. W., Brun, T., et al. A combined PET/CT scanner for clinical oncology. Journal of Nuclear Medicine 41, 1369-1379 (2000).
82. Wu, X., Dibiase, S. J., Gullapalli, R., et al. Deformable image registration for the use of magnetic resonance spectroscopy in prostate treatment planning. International Journal of Radiation Oncology Biology Physics 58, 1577-1583 (2004).
83. Cox, R. W., Jesmanowicz, A., Hyde, J. S. Real-time functional magnetic resonance imaging. Magnetic Resonance in Medicine 33, 230-236 (1995).